Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01773785 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer
A Phase 2 study, sponsored by Spectrum Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT01773785 is a Phase 2 study that was terminated before completion, run by Spectrum Pharmaceuticals. The registered enrollment target is 30 participants.
The verdict
NCT01773785, a Phase 2 study, was terminated before completion, sponsored by Spectrum Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine the effectiveness of SPI-1620 in combination with docetaxel in patients with advanced biliary cancer.
Interventions
- DRUG Docetaxel
- DRUG SPI-1620
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2013-04 |
| Est. Completion | 2015-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01773785
The ClinicalTrials.gov registry entry for NCT01773785 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Spectrum Pharmaceuticals, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Docetaxel is the first listed.
NCT01773785 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01773785 about?
NCT01773785 is a clinical study titled "Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer". The primary purpose of this study is to determine the effectiveness of SPI-1620 in combination with docetaxel in patients with advanced biliary cancer.
What is the current status of trial NCT01773785?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2013-04. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01773785?
The interventions under investigation include: Docetaxel (DRUG), SPI-1620 (DRUG).
Who is sponsoring clinical trial NCT01773785?
This trial is sponsored by Spectrum Pharmaceuticals, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.